Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose epoetin beta for wound healing in diabetic foot ulcer
2006-002758-31Phase 2Completed
- Sponsor
- EPOPLUS
- Start
- Aug 2006
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and diabetic foot ulcer (DFU) comparing epoetin beta with placebo (2 arms). Primary endpoint: Complete wound closure of target ulcer. Started Aug 2006; status: completed.
02
Drugs
epoetin beta
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on 2006-002758-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002758-31.